Trials / Completed
CompletedNCT01271426
Response to Ranibizumab in Polypoidal Choroidal Vasculopathy (PCV)and SNPs
Association of Complement Factor H and ARMS2 Genotypes With Response of Polypoidal Choroidal Vasculopathy to Intravitreal Ranibizumab
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 74 (actual)
- Sponsor
- Nihon University · Academic / Other
- Sex
- All
- Age
- 50 Years
- Healthy volunteers
- Not accepted
Summary
To determine whether complement factor H (CFH) and age-related maculopathy susceptibility 2 (ARMS2) genotypes have a pharmacogenetic effect on the treatment of polypoidal choroidal vasculopathy (PCV) with ranibizumab.
Conditions
Timeline
- Start date
- 2008-04-01
- Primary completion
- 2010-03-01
- Completion
- 2010-03-01
- First posted
- 2011-01-06
- Last updated
- 2011-01-06
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT01271426. Inclusion in this directory is not an endorsement.